4 years safety of fingolimod in real world: PANGAEA, a non-interventional study of safety, effectiveness and pharmacoeconomic data for fingolimod patients in daily clinical practice

被引：0
|
作者：
Ziemssen, T.
Albrecht, H.
Haas, J. [1 ]
Klotz, L. [2 ]
Lang, M. [3 ]
Lassek, C.
Schmidt, S.
Tackenberg, B. [4 ]
Cornelissen, C.
机构：
[1] Jud Krankenhaus, Berlin, Germany
[2] Unilkin Munster, Klin Allgemeine Neurol, Munster, Germany
[3] NTD Study Grp, Ulm, Germany
[4] Univ Klinikum Giessen & Marburg, Marburg, Germany
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2016年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P21143
引用
收藏
页码：416 / 416
页数：1
相关论文
共 50 条
  • [21] Young adult RRMS patients treated with fingolimod in daily clinical practice: interim results of the non-interventional study PANGAEA
    Ziemsseni, T.
    Albrecht, H.
    Haas, J.
    Klotz, L.
    Lang, M.
    Lassek, C.
    Schmidt, S.
    Tackenberg, B.
    Cornelissen, C.
    Ettle, B.
    Schulze-Topphoff, U.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 500 - 500
  • [22] 4 years PANGAEA: long-term data on effectiveness and safety from patients on natalizumab switching to fingolimod in real world
    Ziemssen, T.
    Albrecht, H.
    Haas, J.
    Klotz, L.
    Lang, M.
    Lassek, C.
    Schmidt, S.
    Tackenberg, B.
    Cornelissen, C.
    EUROPEAN JOURNAL OF NEUROLOGY, 2016, 23 : 416 - 416
  • [23] 5 years PANGAEA: Effectiveness of fingolimod in daily clinical practice of RRMS patients in Germany
    Ziemssen, T.
    Albrecht, H.
    Haas, J.
    Klotz, L.
    Lang, M.
    Lassek, C.
    Schmidt, S.
    Tackenberg, B.
    Cornelissen, C.
    EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 657 - 657
  • [24] Study design of PANGAEA 2.0, a non-interventional study on RRMS patients to be switched to fingolimod
    Tjalf Ziemssen
    Raimar Kern
    Christian Cornelissen
    BMC Neurology, 16
  • [25] Study design of PANGAEA 2.0, a non-interventional study on RRMS patients to be switched to fingolimod
    Ziemssen, Tjalf
    Kern, Raimar
    Cornelissen, Christian
    BMC NEUROLOGY, 2016, 16
  • [26] Patients switching to fingolimod in daily clinical routine: 2 year interim results from the non-interventional study PANGAEA 2.0
    Schulze-Topphoff, U.
    Ettle, B.
    Cornelissen, C.
    Ziemssen, T.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 932 - 932
  • [27] Development of former fingolimod study patients in a real world setting: results from the 4 year interim analysis of the non-interventional trial PANGAEA
    Ziemssen, T.
    Albrecht, H.
    Haas, J.
    Klotz, L.
    Lang, M.
    Lassek, C.
    Schmidt, S.
    Tackenberg, B.
    Cornelissen, C.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 643 - 644
  • [28] The PANGAEA study design - a prospective, multicenter, non-interventional, long-term study on fingolimod for the treatment of multiple sclerosis in daily practice
    Ziemssen, Tjalf
    Kern, Raimar
    Cornelissen, Christian
    BMC NEUROLOGY, 2015, 15
  • [29] The PANGAEA study design – a prospective, multicenter, non-interventional, long-term study on fingolimod for the treatment of multiple sclerosis in daily practice
    Tjalf Ziemssen
    Raimar Kern
    Christian Cornelissen
    BMC Neurology, 15
  • [30] Study design of a non-interventional registry study to establish long-term safety and pharmaco-economic data on fingolimod (Gilenya®) in multiple sclerosis patients (PANGAEA)
    van Lokven, T.
    Kempcke, R.
    Ziemssen, T.
    Meergans, M.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S213 - S214
12345